This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AC3056

Sanofi

Drug Names(s): AC3056

Description: Preclinical investigation demonstrates that AC3056 has favorable effects at the level of various biochemical mediators of the atherosclerotic process. In various animals, the agent reduces serum low density lipoproteins (LDLs), but not serum high density lipoproteins (HDLs), inhibits lipoprotein oxidation, and inhibits cell adhesion molecules in vascular cells. Orally active, its antioxidant effects and effects at the level of lipoproteins inhibited atherosclerotic plaque formation in relevant arterial walls and prevented cholesterol-precipitated functional damage to blood vessels.

Deal Structure: AC3056 was originally in-licensed from Aventis.

In the second quarter of 2005, Amylin terminated its collaboration agreement with Sanofi-Aventis for AC3056 and all rights to that compound reverted to Sanofi-Aventis.


AC3056 News

Pink Sheet In Brief: BASF


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug